Preeclampsia
Conditions
Brief summary
The goal of this clinical trial is to learn if allied-health professionals can recruit and follow research participants, sustain engagement, and improve and diagnose treatment of diseases by facilitating transitions of care. Participants will: Take their blood pressure at home and return it to the research team; Follow up with a research pharmacist for 12 months; Return for a follow up visit after 12 months.
Detailed description
After consent, a research pharmacist will virtually monitor the participant's blood pressure until the 12-month follow up visit. The research pharmacists will have access to the participant's electronic medical records to monitor and document medications and clinic blood pressures for analysis . Participants will be asked to measure and return 14 blood pressure measurements (2x per day for 7 days) using our text messaging platform. They will be allowed to choose the times that they are sent reminders to measure their blood pressure. If a participant has blood pressure values sufficient for a hypertension diagnosis, the pharmacist will communicate via electronic medical record with the participant's primary care team. If they do not have a primary care provider, the pharmacist will facilitate finding one. The pharmacist will continue monitoring the participant and making recommendations to the primary care team through the electronic medical record to quickly adjust therapy to improve blood pressure control. The pharmacists will typically contact the participants (via participant's choice of phone, text, or email) every 2-3 weeks while their hypertension is uncontrolled. Once under control, the pharmacist will continue to contact the participant at least every 2 months to support adherence and reassess control.
Interventions
BEHAVIORALResearch Pharmacist
The goal of this intervention is to determine if allied health professionals will improve blood pressure in new mothers.
Sponsors
University of Iowa
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Biological mothers delivering at UIHC or attending a well-child visit for an infant between 1 month and 9 months * Preeclampsia during pregnancy * Preceived prenatal care at UIHC * Owns a smartphone
Exclusion criteria
* Arm circumference greater than 17 inches * Prisoner status * Unable to provide own written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects at Risk for Hypertension | Through study completion, an average of 12 months | We will calculate the number of participants who are at risk for hypertension during the course of the intervention. |
| Number of Subjects Exposed to a Screening Clinic | Through study completion, an average of 12 months | We will calculate the number of participants who visited a screening clinic during the course of the intervention. |
| Number of Subjects Screened at a Screening Clinic | Through study completion, an average of 12 months | We will calculate the number of participants who were screened at a screening clinic during the intervention. |
| Number of Subjects Followed-Up by the Research Pharmacist | Through study completion, an average of 12 months | We will calculated the number of participants who were followed-up by a research pharmacist during the intervention. |
| Number of Subjects Diagnosed with Hypertension | Through study completion, an average of 12 months | We will calculate the number of participants who were diagnosed with hypertension by their provider during the intervention. |
| Number of Subjects Treated for Hypertension, if Diagnosed | Through study completion, an average of 12 months | We will calculate the number of participants who were treated for their hypertension diagnosis by their provider, if they were diagnosed with hypertension, during the intervention. |
Contacts
CONTACTPhilip M Polgreen, MD
CONTACTShelby L Francis, PhD
PRINCIPAL_INVESTIGATORPhilip M Polgreen, MD
University of Iowa
Outcome results
None listed